Valuation: MiMedx Group, Inc.

Capitalization 1.17B 1.08B 1.03B 906M 1.68B 101B 1.87B 11.85B 4.53B 44.21B 4.39B 4.3B 174B P/E ratio 2025 *
29.4x
P/E ratio 2026 * 22.2x
Enterprise value 1.17B 1.08B 1.03B 906M 1.68B 101B 1.87B 11.85B 4.53B 44.21B 4.39B 4.3B 174B EV / Sales 2025 *
3.11x
EV / Sales 2026 * 2.79x
Free-Float
97.55%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.38%
1 week+0.25%
Current month-5.53%
1 month-0.50%
3 months-12.75%
6 months+29.53%
Current year-17.46%
More quotes
1 week
7.74
Extreme 7.74
8.13
1 month
7.38
Extreme 7.375
8.46
Current year
7.38
Extreme 7.375
9.71
1 year
5.47
Extreme 5.47
10.14
3 years
2.43
Extreme 2.43
10.14
5 years
2.43
Extreme 2.43
15.99
10 years
0.95
Extreme 0.95
18.25
More quotes
Manager TitleAgeSince
Chief Executive Officer 62 2023-01-26
Director of Finance/CFO 59 2023-07-04
Chief Tech/Sci/R&D Officer - 2021-05-31
Director TitleAgeSince
Director/Board Member 72 2019-06-18
Chairman 72 2019-06-18
Director/Board Member 62 2019-06-18
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.38%+0.25%-2.70%+67.51% 1.17B
-1.16%+0.07%-16.84%-32.93% 108M
-1.23%-6.40%-26.82%-74.84% 50.72M
Average -0.92%-1.91%-15.45%-13.42% 442.91M
Weighted average by Cap. -0.48%+0.01%-4.77%+53.92%
See all sector performances

Financials

2025 *2026 *
Net sales 376M 348M 332M 291M 540M 32.34B 600M 3.81B 1.46B 14.21B 1.41B 1.38B 56.07B 420M 388M 371M 325M 602M 36.11B 669M 4.25B 1.63B 15.86B 1.57B 1.54B 62.59B
Net income 40.3M 37.26M 35.6M 31.22M 57.82M 3.47B 64.27M 408M 156M 1.52B 151M 148M 6.01B 54.35M 50.25M 48.02M 42.1M 77.98M 4.67B 86.68M 551M 211M 2.05B 204M 200M 8.1B
Net Debt - -
More financial data * Estimated data
Logo MiMedx Group, Inc.
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
Employees
837
More about the company
Date Price Change Volume
25-03-21 7.940 $ -0.38% 1,166,285
25-03-20 7.970 $ -1.48% 334,244
25-03-19 8.090 $ +2.15% 440,961
25-03-18 7.920 $ -1.49% 366,929
25-03-17 8.040 $ +1.52% 461,090

Delayed Quote Nasdaq, March 21, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.940USD
Average target price
13.40USD
Spread / Average Target
+68.77%
Consensus

Quarterly revenue - Rate of surprise